ECSP21003718A - Derivados de triazolquinoxalina adicionalmente sustituidos - Google Patents

Derivados de triazolquinoxalina adicionalmente sustituidos

Info

Publication number
ECSP21003718A
ECSP21003718A ECSENADI20213718A ECDI202103718A ECSP21003718A EC SP21003718 A ECSP21003718 A EC SP21003718A EC SENADI20213718 A ECSENADI20213718 A EC SENADI20213718A EC DI202103718 A ECDI202103718 A EC DI202103718A EC SP21003718 A ECSP21003718 A EC SP21003718A
Authority
EC
Ecuador
Prior art keywords
triazolquinoxaline
additionally substituted
derivatives additionally
derivatives
glucocorticoid receptor
Prior art date
Application number
ECSENADI20213718A
Other languages
English (en)
Inventor
Florian Jakob
Tobias Craan
Sebastian Wachten
Achim Kless
Paul Ratcliffe
Jo Alen
Simon Lucas
Ingo Konetzki
Stefan Schunk
Simon Cruwys
Original Assignee
Gruenenthal Gmbh [De/De]
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh [De/De] filed Critical Gruenenthal Gmbh [De/De]
Publication of ECSP21003718A publication Critical patent/ECSP21003718A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de acuerdo con la fórmula general (I) que actuan como moduladores del receptor de glucocorticoides y se pueden usar para el tratamiento y/o la profilaxis de trastornos que son mediados parcialmente con el receptor de glucocorticoides.
ECSENADI20213718A 2018-07-20 2021-01-18 Derivados de triazolquinoxalina adicionalmente sustituidos ECSP21003718A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18184607 2018-07-20

Publications (1)

Publication Number Publication Date
ECSP21003718A true ECSP21003718A (es) 2021-02-26

Family

ID=63014345

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20213718A ECSP21003718A (es) 2018-07-20 2021-01-18 Derivados de triazolquinoxalina adicionalmente sustituidos

Country Status (29)

Country Link
US (3) US10981918B2 (es)
EP (1) EP3823970B1 (es)
JP (1) JP7336505B2 (es)
KR (1) KR102798858B1 (es)
CN (1) CN112771046B (es)
AR (1) AR117951A1 (es)
AU (1) AU2019304085B2 (es)
BR (1) BR112021000857A2 (es)
CA (1) CA3106778A1 (es)
CL (1) CL2021000126A1 (es)
CO (1) CO2021000292A2 (es)
DK (1) DK3823970T3 (es)
EA (1) EA202190272A1 (es)
EC (1) ECSP21003718A (es)
ES (1) ES2973525T3 (es)
FI (1) FI3823970T3 (es)
HR (1) HRP20240429T1 (es)
HU (1) HUE065896T2 (es)
IL (1) IL280211B2 (es)
LT (1) LT3823970T (es)
MX (1) MX2021000759A (es)
PE (1) PE20211377A1 (es)
PL (1) PL3823970T3 (es)
PT (1) PT3823970T (es)
RS (1) RS65245B1 (es)
SI (1) SI3823970T1 (es)
TW (1) TWI811400B (es)
WO (1) WO2020016452A1 (es)
ZA (1) ZA202100672B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3104199A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
US10981918B2 (en) * 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives
WO2020016453A1 (en) * 2018-07-20 2020-01-23 Grünenthal GmbH Substituted triazolo quinoxaline derivatives
PE20211811A1 (es) 2018-07-20 2021-09-14 Hoffmann La Roche Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
ES2976780T3 (es) * 2020-01-17 2024-08-08 Gruenenthal Gmbh Derivados de quinoxalina
EP4090661B1 (en) * 2020-01-17 2025-03-12 Grünenthal GmbH Quinoxaline derivatives as modulators of the glucocorticoid receptor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
EP1583745A1 (en) * 2003-01-03 2005-10-12 Boehringer Ingelheim Pharmaceuticals Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
DE602004026558D1 (de) * 2003-02-25 2010-05-27 Merck Sharp & Dohme Selektive nichtsteroidale glucocorticoid-rezeptor- modulatoren
US7662846B2 (en) * 2003-04-23 2010-02-16 Merck Sharp & Dohme Corp. Selective spirocyclic glucocorticoid receptor modulators
US7569689B2 (en) * 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
KR20070056060A (ko) 2004-07-14 2007-05-31 리간드 파마슈티칼스 인코포레이티드 세포내 수용체 조절화합물 및 방법
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor
MX2008009475A (es) * 2006-01-23 2008-10-20 Amira Pharmaceuticals Inc Inhibidores triciclicos de 5-lipoxigenasa.
PL1995242T3 (pl) * 2006-03-14 2013-03-29 Santen Pharmaceutical Co Ltd Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy
KR20090020694A (ko) * 2006-07-14 2009-02-26 일라이 릴리 앤드 캄파니 글루코코르티코이드 수용체 조절제 및 이의 사용 방법
WO2008146871A1 (ja) * 2007-05-29 2008-12-04 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
WO2009003567A1 (fr) 2007-06-29 2009-01-08 Johnson Controls Technology Company Procede de montage d'un composant electrique sur un element de support et dispositif de raccordement electrique
JP2009046435A (ja) 2007-08-21 2009-03-05 Mitsubishi Tanabe Pharma Corp グルココルチコイド受容体モジュレーター
WO2009035067A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト
JP2009084274A (ja) * 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd 新規１，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体
WO2009103007A2 (en) 2008-02-13 2009-08-20 Ligand Pharmaceuticals Incorporated Steroid hormone receptor modulator compounds and methods
EP2334671A1 (en) * 2008-06-24 2011-06-22 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
KR20110053467A (ko) * 2008-09-12 2011-05-23 산텐 세이야꾸 가부시키가이샤 술폰산에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2,3,4-테트라히드로퀴녹살린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
MX368167B (es) * 2013-11-25 2019-09-23 Corcept Therapeutics Inc Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
JP2017043614A (ja) 2015-08-25 2017-03-02 参天製薬株式会社 ［４−（１，３，３−トリメチル−２−オキソ−３，４−ジヒドロ−１ｈ−キノキサリン−７−イル）フェノキシ］エチルオキシ化合物またはその塩
CA3049608A1 (en) * 2017-01-09 2018-07-12 Suixiong Cai Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof
US10981918B2 (en) 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives
WO2020016453A1 (en) * 2018-07-20 2020-01-23 Grünenthal GmbH Substituted triazolo quinoxaline derivatives

Also Published As

Publication number Publication date
BR112021000857A2 (pt) 2021-04-13
CN112771046B (zh) 2023-09-19
US20200024281A1 (en) 2020-01-23
AR117951A1 (es) 2021-09-08
MX2021000759A (es) 2021-03-29
DK3823970T3 (da) 2024-02-05
WO2020016452A1 (en) 2020-01-23
CN112771046A (zh) 2021-05-07
IL280211A (en) 2021-03-01
PT3823970T (pt) 2024-03-27
CA3106778A1 (en) 2020-01-23
HUE065896T2 (hu) 2024-06-28
SI3823970T1 (sl) 2024-03-29
TWI811400B (zh) 2023-08-11
US20240327416A1 (en) 2024-10-03
RS65245B1 (sr) 2024-03-29
HRP20240429T1 (hr) 2024-08-16
NZ772720A (en) 2024-08-30
EA202190272A1 (ru) 2021-06-21
US10981918B2 (en) 2021-04-20
KR102798858B1 (ko) 2025-04-23
IL280211B2 (en) 2024-09-01
JP7336505B2 (ja) 2023-08-31
LT3823970T (lt) 2024-02-12
US11981677B2 (en) 2024-05-14
KR20210034632A (ko) 2021-03-30
CL2021000126A1 (es) 2021-07-19
JP2021532100A (ja) 2021-11-25
EP3823970A1 (en) 2021-05-26
AU2019304085B2 (en) 2024-09-05
EP3823970B1 (en) 2024-01-03
ES2973525T3 (es) 2024-06-20
AU2019304085A1 (en) 2021-03-04
PL3823970T3 (pl) 2024-04-22
CO2021000292A2 (es) 2021-01-29
PE20211377A1 (es) 2021-07-27
FI3823970T3 (fi) 2024-02-01
ZA202100672B (en) 2024-09-25
IL280211B1 (en) 2024-05-01
TW202007687A (zh) 2020-02-16
US20210163491A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
ECSP21051067A (es) Amidas de pirrolidina III sustituidas
ECSP21003718A (es) Derivados de triazolquinoxalina adicionalmente sustituidos
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CL2018002671A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CO2019007881A2 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
CO2019007882A2 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
MX2019004030A (es) Inhibidores del receptor de glucocorticoides.
MX2020006348A (es) Pirrolidinamidas i sustituidas.
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MX2019000136A (es) Composiciones de acido cromoglicico para tratamiento de dermatitis.